AI Verdict
EQT has stronger fundamentals based on our AI analysis.
ERNAW vs EQT Fundamental Comparison
| Metric | ERNAW | EQT |
|---|---|---|
| Revenue | $582,000.0 | $8.6B |
| Net Income | $-14.1M | $2.0B |
| Net Margin | -2,419.9% | 23.6% |
| ROE | -586.6% | 8.6% |
| ROA | -241.4% | 4.9% |
| Current Ratio | 1.01x | 0.76x |
| Debt/Equity | 0.22x | 0.33x |
| EPS | $-2.24 | $3.31 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
ERNAW vs EQT: Frequently Asked Questions
Is ERNAW or EQT a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), EQT has stronger fundamentals. ERNAW is rated STRONG SELL (95% confidence) while EQT is rated BUY (78% confidence). This is not investment advice.
How does ERNAW compare to EQT fundamentally?
Ernexa Therapeutics Inc. has ROE of -586.6% vs EQT Corp's 8.6%. Net margins are -2,419.9% vs 23.6% respectively.
Which stock pays higher dividends, ERNAW or EQT?
ERNAW has a dividend yield of N/A or no dividend while EQT has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in ERNAW or EQT for long term?
For long-term investing, consider that ERNAW has STRONG SELL rating with 95% confidence, while EQT has BUY rating with 78% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about ERNAW vs EQT?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For ERNAW vs EQT, the AI consensus favors EQT based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.